Continuing access to ATH434 after the earlier study
Part of Brain & nervous system clinical trials.
This trial lets people who finished the earlier ATH434-201 study keep getting ATH434 (an experimental drug) on an open-label basis, meaning everyone knows they get the drug. If you were in that study and want to continue, this may help you keep receiving the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier ATH434-201 study.
- You and your doctor must agree that you might still benefit from more ATH434 treatment.
- You cannot have stopped the earlier ATH434 treatment for any reason.
- You should not have serious medical or mental health conditions that could make it unsafe to continue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program lets people who already completed a study of the drug ATH434 for multiple system atrophy continue getting the treatment. It is for patients whose doctors believe they may benefit from staying on the medication.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
This trial provides continued access to an investigational drug (TRx0237) for people with early or mild-moderate Alzheimer's disease. It aims to see if long-term use is safe and beneficial.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
This study lets people who were already getting benefit from a Lilly study treatment keep taking it after the main study ends, so doctors can continue to monitor their safety.
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.